RT Journal Article
T1 Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia.
A1 Cuadros, Marta
A1 Andrades, Alvaro
A1 Coira, Isabel F
A1 Baliñas, Carlos
A1 Rodriguez, Maria I
A1 Alvarez-Perez, Juan Carlos
A1 Peinado, Paola
A1 Arenas, Alberto M
A1 Garcia, Daniel J
A1 Jimenez, Pilar
A1 Camos, Mireia
A1 Jimenez-Velasco, Antonio
A1 Medina, Pedro P
K1 Biomarkers, Tumor
K1 Core Binding Factor Alpha 2 Subunit
K1 Gene Expression Profiling
K1 Gene Expression Regulation, Neoplastic
AB Acute lymphoblastic leukemia (ALL) is a clinically and biologically heterogeneous disease recurrently affected by chromosomal aberrations, including translocations, amplifications, and aneuploidies1. These aberrations have important implications for the diagnosis, sub-classification, prognosis and, overall, for making appropriate therapeutic decisions. The reciprocal translocation t(12;21)(p13;q22)[ETV6/RUNX1] is the most frequent chromosomal rearrangement in pediatric B-cell acute lymphoblastic leukemia (B-ALL) with an incidence of ~25%2. This rearrangement, as well as high hyperdiploidy, is associated with a favorable outcome under current treatment protocols, but up to 20% of ETV6-RUNX1positive pediatric B-ALL patients experience a late disease relapse1,3.
PB Nature Publishing Group
YR 2019
FD 2019-11-25
LK http://hdl.handle.net/10668/14742
UL http://hdl.handle.net/10668/14742
LA en
NO Cuadros M, Andrades Á, Coira IF, Baliñas C, Rodríguez MI, Álvarez-Pérez JC, et al. Expression of the long non-coding RNA TCL6 is associated with clinical outcome in pediatric B-cell acute lymphoblastic leukemia. Blood Cancer J. 2019 Nov 25;9(12):93
NO The authors would like to thank the Deutsche José Carreras Leukämie-Stiftung, Inocente Inocente Foundation, the Ministry of Economy of Spain SAF201567919-R), Consejería de Salud de la Junta de Andalucía (Pl-0245-2017, CS20163), BBVA Foundation, Francisco-Cobos Foundation, Fero Foundation and AECC Foundation for funding Pedro P. Medinas’s lab. Álvaro Andrades is supported by an FPU17/00067 PhD fellowship, Alberto M. Arenas is supported by an FPU17/01258 PhD fellowship, Paola Peinado is supported by a La Caixa Foundation PhD Fellowship (LCF/BQ/DE15/10360019), Isabel F. Coira was supported by a PhD FPI-fellowship (BES-2013-064596), Daniel J. García is supported by a Fundación Benéfica Anticáncer Santa Cándida y San Francisco Javier PhD fellowship and Juan Carlos Álvarez-Pérez is supported by a Marie Sklodowska Curie action (H2020-MSCA-IF-2018). 
DS RISalud
RD Apr 7, 2025